Bevacizumab in Treating Patients With Relapsed Prostate Cancer That Did Not Respond to Hormone Therapy

Part of paid clinical trials in Detroit, Michigan.

Sponsor
Barbara Ann Karmanos Cancer Institute
Study ID
NCT01656304
Phase
PHASE2
Status
Completed

Conditions

  • Adenocarcinoma of the Prostate
  • Recurrent Prostate Cancer
  • Stage I Prostate Cancer
  • Stage IIA Prostate Cancer
  • Stage IIB Prostate Cancer
  • Stage III Prostate Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • bevacizumab — BIOLOGICAL
    Given IV
  • laboratory biomarker analysis — OTHER
    Correlative studies

Study Details

This pilot phase II trial studies how well giving bevacizumab works in treating patients with relapsed prostate cancer that did not respond to hormone therapy. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or tumor-killing substances to them. Bevacizumab may also stop the growth of prostate cancer by blocking blood flow to the tumor

Key Dates

First listed
Aug 2, 2012
Start date
May 31, 2007
Status verified
Jul 2018
Primary completion
Jan 31, 2012
Completion
Jun 30, 2012

Study Design

Enrollment
16 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment (monoclonal antibody, antiangiogenesis)
    Patients receive bevacizumab IV over 30-90 minutes once every 14 days. Courses repeat every 14 days in the absence of disease progression and unacceptable toxicity.

Primary Outcome Measure

PSA Response Rate With Bevacizumab Therapy in Androgen Independent Non-metastatic Prostate Cancer [ Time Frame: An average every 6 weeks for up to 3 months ]

Locations (2)

FacilityCityStateZIPSite coordinators
Barbara Ann Karmanos Cancer InstituteDetroitMichigan48201-
Henry Ford HospitalDetroitMichigan48202-

Find similar trials in Detroit, MI

By research site
Barbara Ann Karmanos Cancer Institute· Detroit, MIHenry Ford Hospital· Detroit, MI

Related Studies